Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab

• Published in: Blood Vol. 133; no. 19; pp. 2031 - 2042
• Main Authors: Byrd, John C., Hillmen, Peter, O'Brien, Susan, Barrientos, Jacqueline C., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Barr, Paul M., Furman, Richard R., Kipps, Thomas J., Thornton, Patrick, Moreno, Carol, Montillo, Marco, Pagel, John M., Burger, Jan A., Woyach, Jennifer A., Dai, Sandra, Vezan, Remus, James, Danelle F., Brown, Jennifer R.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 09.05.2019; American Society of Hematology
• Subjects: Adenine - analogs & derivatives; Adult; Aged; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents, Immunological - therapeutic use; Clinical Trials and Observations; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Male; Middle Aged; Piperidines; Progression-Free Survival; Pyrazoles - therapeutic use; Pyrimidines - therapeutic use; Time
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood-2018-08-870238

Ibrutinib, a once-daily oral inhibitor of Bruton tyrosine kinase, has greatly improved outcomes for patients with chronic lymphocytic leukemia (CLL). The phase 3 RESONATE trial, which compared single-agent ibrutinib to ofatumumab in high-risk, relapsed patients with CLL, provided support for approva...